These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 2512592)

  • 1. The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study.
    Stambuk D; Youle M; Hawkins D; Farthing C; Shanson D; Farmer R; Lawrence A; Gazzard B
    Q J Med; 1989 Feb; 70(262):161-74. PubMed ID: 2512592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zidovudine treatment of patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex: St Stephen's Hospital experience.
    Stambuk D; Hawkins D; Gazzard BG
    J Infect; 1989 Jan; 18 Suppl 1():41-51. PubMed ID: 2492585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
    Fischl MA; Richman DD; Grieco MH; Gottlieb MS; Volberding PA; Laskin OL; Leedom JM; Groopman JE; Mildvan D; Schooley RT
    N Engl J Med; 1987 Jul; 317(4):185-91. PubMed ID: 3299089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
    Richman DD; Fischl MA; Grieco MH; Gottlieb MS; Volberding PA; Laskin OL; Leedom JM; Groopman JE; Mildvan D; Hirsch MS
    N Engl J Med; 1987 Jul; 317(4):192-7. PubMed ID: 3299090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group.
    McKinney RE; Maha MA; Connor EM; Feinberg J; Scott GB; Wulfsohn M; McIntosh K; Borkowsky W; Modlin JF; Weintrub P
    N Engl J Med; 1991 Apr; 324(15):1018-25. PubMed ID: 1672443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of low-dose zidovudine in human immunodeficiency virus infection.
    Collier AC; Bozzette S; Coombs RW; Causey DM; Schoenfeld DA; Spector SA; Pettinelli CB; Davies G; Richman DD; Leedom JM
    N Engl J Med; 1990 Oct; 323(15):1015-21. PubMed ID: 1977080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behaviour of different clinical, immunological and serological parameters observed in a group of HIV positive patients during a 12 month treatment period with zidovudine.
    Crocchiolo PR; Lizioli A; Arcidiacono I; Cantaluppi P; Filippi C; Sobatti D; Bedarida G; D'Agostino F; Cambie G; Nardella ML
    Boll Ist Sieroter Milan; 1990 Jun; 69(2):423-30. PubMed ID: 1983798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of treatment with AZT of patients with AIDS and symptomatic HIV infection.
    Cox PH; Martin MA; Styer CM; Beall GN
    Nurse Pract; 1990 May; 15(5):36, 39-44. PubMed ID: 2342666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of azidothymidine (AZT) on P24 antigen levels in patients with AIDS-related complex and AIDS.
    Reddy MM; McKinley G; Englard A; Grieco MH
    J Clin Lab Anal; 1989; 3(4):199-201. PubMed ID: 2503599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
    Fischl MA; Parker CB; Pettinelli C; Wulfsohn M; Hirsch MS; Collier AC; Antoniskis D; Ho M; Richman DD; Fuchs E
    N Engl J Med; 1990 Oct; 323(15):1009-14. PubMed ID: 1977079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human erythropoietin for patients with AIDS treated with zidovudine.
    Fischl M; Galpin JE; Levine JD; Groopman JE; Henry DH; Kennedy P; Miles S; Robbins W; Starrett B; Zalusky R
    N Engl J Med; 1990 May; 322(21):1488-93. PubMed ID: 2186273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
    Chaisson RE; Moore RD; Richman DD; Keruly J; Creagh T
    Am Rev Respir Dis; 1992 Aug; 146(2):285-9. PubMed ID: 1362634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex.
    Schmitt FA; Bigley JW; McKinnis R; Logue PE; Evans RW; Drucker JL
    N Engl J Med; 1988 Dec; 319(24):1573-8. PubMed ID: 3059187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
    Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfusion associated AIDS in Mexico. Clinical spectrum, conditional latency distribution, and survival.
    Volkow P; Ponce de León S; Calva J; Ruiz-Palacios G; Mohar A
    Rev Invest Clin; 1993; 45(2):133-8. PubMed ID: 8337540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum p24 antigen levels in untreated and zidovudine-treated HIV-1 infected subjects.
    Mulder JW; Lange JM; de Wolf F; Houweling JT; Bakker M; Coutinho RA; Goudsmit J
    Neth J Med; 1990 Aug; 37(1-2):4-10. PubMed ID: 2120599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.
    Cooley TP; Kunches LM; Saunders CA; Ritter JK; Perkins CJ; McLaren C; McCaffrey RP; Liebman HA
    N Engl J Med; 1990 May; 322(19):1340-5. PubMed ID: 2139174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
    Whitfield RM; Bechtel LM; Starich GH
    Alcohol Clin Exp Res; 1997 Feb; 21(1):122-7. PubMed ID: 9046384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.